Ask AI
Frontline Management of Transplant Ineligible MM

CE

Frontline Management of Transplant-Ineligible Multiple Myeloma: Optimizing Therapy, Supportive Care, and Patient Outcomes

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 31, 2026

Expiration: January 30, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Facon T, Leleu X, Manier S. How I treat multiple myeloma in geriatric patients. Blood. 2024;143:224-232.
  2. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.
  3. Facon T, Moreau P, Weisel K, et al. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39:942-950.
  4. Facon T, Kumar S, Orlowski RZ, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. Presented at: 2024 European Hematology Association Annual Conference; June 13-16, 2024. Abstract P968.
  5. Leleu X, Hulin C, Lambert J, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235-2241.
  6. Facon T, Dimopoulos M-A, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597-1609.
  7. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat Med. 2025;31:1195-1202.
  8. Harding S, Mikhael J. Down with dex! Blood. 2025;145:3-4.
  9. Usmani SZ, Nahi H, Legiec W, et al. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022;107:2408-2417.
  10. Ailawadhi S, Špička I, Spencer A, et al. Isatuximab subcutaneous by on-body delivery system vs isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: phase 3 IRAKLIA study. J Clin Oncol. 2025;43:2527-2537.
  11. Parmar G, Capra M, Seguro F, et al. Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the phase 2 study IZALCO. Blood Cancer J. 2025;16:16.
  12. Bobin A, Zhang R, Morisse M, et al. Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: final analysis of the ISASOCUT study (IFM 2022-05). Presented at: 2025 American Society of Hematology Annual Conference; December 6-9, 2025. Abstract 2275.
  13. Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143-e161.
  14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. v.5.2026. nccn.org. Accessed July 28, 2026.
  15. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-3120.